Diskussionsleiter: I. Ott (München)
| (P1738) | Platelet surface activation markers in patients with acute venous thromboembolism – results from the VTEval project | |
| M. Paul, M. Nagler, H. Lamparter, J. Prochaska, N. Arnold, H. M. Spronk, K. Jurk, G. Weisser, C. Espinola-Klein, S. Konstantinides, K. Lackner, T. Münzel, H. ten Cate, P. S. Wild, M. Panova-Noeva (Mainz; Maastricht, NL) | ||
| (P1739) | Arterial and venous thromboembolic events in cancer patients treated with bevacizumab – a meta-analysis of over 21,000 oncologic patients | |
| R. Mincu, T. Rassaf, M. Totzeck (Essen) | ||
| (P1740) | Thromboxane formation assay to identify high on-treatment platelet reactivity to aspirin | |
| L. K. Dannenberg, A. Mohring, C. Helten, K. Bartkowski, T. Zeus, M. Kelm, T. Hohlfeld, A. Polzin (Düsseldorf) | ||
| (P1741) | Die antithrombotische Triple-Therapie bei Patienten mit Indikation zur dauerhaften oralen Antikoagulation und zusätzlicher Koronarintervention: eine Querschnittsanalyse |
|
| H. Ullrich, M. Behnes, E. Ligtenberg, A. Elsässer, P. Boekstegers, H. Eggebrecht, H. Thiele, T. Münzel, I. Akin, T. Gori (Mainz, Mannheim, Oldenburg, Siegburg, Frankfurt am Main, Lübeck) | ||
| (P1742) | Pharmacosimulation of Interruptions and its Solution in Intravenous Administration of Cangrelor | |
| M. Masyuk, N. Heramvand, J. Müssig, A. Polzin, A. Nia, M. Kollmann, M. Kelm, C. Jung (Düsseldorf) | ||
| (P1743) | Platelet inhibition with the intravenous P2Y12 receptor inhibitor cangrelor is not influenced by immature platelets | |
| C. Stratz, P. Kleiner, I. Younas, N. Löffelhardt, C. M. Valina, T. Nührenberg, D. Trenk, F.-J. Neumann, W. Hochholzer (Bad Krozingen) |